Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fabien Lavergne
Institution:
Agence Nationale de Sécurité du Médicament et des Produits de Santé
Observed institutions:
Airbus (France),
Centre National de la Recherche Scientifique,
European Medicines Agency,
Laboratoire d'Analyse et d'Architecture des Systèmes,
Agence Nationale de Sécurité du Médicament et des Produits de Santé
ORCID:
0009-0001-1559-6340
Observed ORCID:
0009-0001-1559-6340
OpenAlex ID:
A5059606142
Nonlinear Robust Autoland
2005
·
Fabien Lavergne
, Fabrice Villaume
, et al.
·
AIAA Guidance, Navigation, and Control Conference and Exhibit
·
12
Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective
2019
·
Jan Willem van der Laan
, Karen van Malderen
, et al.
·
International Journal of Toxicology
·
11
PDF
Méthodologie de synthèse de lois de commandes non-linéaires et robustes : Application au suivi de trajectoire des avions de transport
2005
·
Fabien Lavergne
·
HAL
·
5
Neural Networks Contribution to Modeling for Flight Control
2004
·
Fabien Lavergne
, Félix Mora-Camino
, et al.
·
SAE technical papers on CD-ROM/SAE technical paper series
·
2
Translating non-clinical proof-of-concept data into paediatric development decisions: the case of HER2-targeting antibody-drug conjugates
2026
·
Pauliina Lehtolainen-Dalkilic
, Caoimhin G. Concannon
, et al.
·
EJC Paediatric Oncology
PDF
Retrospective (Q)SAR analysis of genotoxicity data from European pharmaceutical scientific advice and authorization procedures and performance improvements using structural alert and chemical subspace analyses, reliability filtering, and expert review
2026
·
Ajouan Mazoudji
, Daniela Digles
, et al.
·
Regulatory Toxicology and Pharmacology
Retrospective (Q)SAR analysis of genotoxicity data from European pharmaceutical scientific advice and authorization procedures and performance improvements using structural alert and chemical subspace analyses, reliability filtering, and expert review
2026
·
Ajouan Mazoudji
, Daniela Digles
, et al.
·
Figshare
Integrating non-clinical and clinical evidence for prioritisation in paediatric oncology drug development: Regulatory experience with three PARP inhibitors
2026
·
Karen Van Malderen
, Sofie Peirs
, et al.
·
EJC Paediatric Oncology
PDF
Show more works
View as search
Works count:
8
Citation count:
30
H-index:
3
I10-index:
2
Year
Topic
Type